Helping our partners as they develop a COVID-19 vaccine.

July 7, 2020 LP Raman

Technician performing bioprocessing application in a lab.

As we continue to face challenging times and develop a plan of action, working together can help us win the battle against COVID-19.

As a part of the fight against this virus, we must collaborate to develop an effective treatment and vaccine. Understanding the characteristics of the COVID-19 virus and developing a vaccine can help us manage this global pandemic and possibly mitigate future outbreaks.

Helping our partners to develop a COVID-19 vaccine.

An essential aspect of the creation of a vaccine is downstream purification and the purification of viral pathogens.

Vaccine manufacturing processes include many upstream and downstream unit operations. Typical downstream operations involve concentrating and isolating the target antigenic molecule and avoiding conditions that could lead to its inactivation and loss, and then removing contaminates and trace impurities. By optimizing downstream purification steps, biopharmaceutical manufactures can reduce the time it takes to develop and produce a vaccine and helping clinical evaluations can take place earlier.

3M brings unique tools to biological drug manufacturing. The 3M™ Emphaze™ AEX Hybrid Purifier chromatographically reduces DNA, HCP, and endotoxin, helping to improve product purity and yield in bioprocess purification trains.

Integrated, scalable, and single-use unit depth filtration products such as 3M™ Zeta Plus™ Encapsulated System can be used to develop effective initial clarification unit operations from the laboratory to commercial production.

Learn more.

We are proud to help our partners succeed as they look for a vaccine to help control the spread of COVID-19.

To learn more about 3M products for Biopharmaceutical Manufacturing, sign up for our virtual Lunch and Learn and visit our page.

About the Author

LP Raman

[enBio=With an MS in Food and Biochemical Engineering from the University of Illinois, LP Raman has spent the last three decades building key biopharma portfolios across the globe. He joined 3M in 2010 and has brought his expertise to the filtration and purification product portfolio while offering critical solutions to our customers in the industry.],[enJob=3M U.S. and Canada Biopharma Portfolio Manager],[frBio=Titulaire d’une maîtrise en génie alimentaire et biochimique de l’Université de l’Illinois, LP Raman a passé les trois dernières décennies à élaborer des portefeuilles biopharmaceutiques clés dans le monde entier. Il s’est joint à 3M en 2010 et a apporté son expertise au service du portefeuille de produits de filtration et de purification tout en offrant des solutions essentielles à nos clients dans l’industrie.],[frJob=Gestionnaire de portefeuille biopharmaceutique de 3M É.-U. et 3M Canada]

More From LP Raman
Previous Article
V.E.I.N.S.S. series, part three: how to avoid infections from PVADs.
V.E.I.N.S.S. series, part three: how to avoid infections from PVADs.

Steps healthcare professionals can take to prevent infection in peripheral venous access devices (PVADs).

Next Article
Proud to be allies for change: how safe spaces support diversity and inclusion.
Proud to be allies for change: how safe spaces support diversity and inclusion.

Learn how safe spaces support diversity and inclusion and promote a positive company culture.